Impact of Response Rates on Overall Survival Following Chemoradiotherapy with or Without Surgery in Esophageal Cancer
Open Access
- 23 February 2026
- journal article
- Published by AVES YAYINCILIK A.Ş. in Cerrahpasa Medical Journal
- Vol. 50, 1-9
Abstract
Objective: Neoadjuvant chemoradiotherapy (NACRT) plays an important role in the treatment of esophageal cancer. Current studies show that increased pathological response and R0-resection rates positively affect treatment outcomes. This study aimed to evaluate the clinical outcomes of patients who received NACRT with or without surgery. Methods: In this study, 72 patients diagnosed with esophageal cancer who underwent NACRT, with or without subsequent surgery, were retrospectively analyzed. Radiotherapy (RT) fields were defined based on the primary tumor location, and the median RT dose was 50.4 Gy (range: 41.4–54 Gy). The patients received a chemotherapy regimen consisting of 5 cycles of carboplatin and paclitaxel. Following CRT, patients who were eligible for surgery depending on their pathological response rates underwent surgical resection. Results: Overall survival and progression-free survival were found to be statistically significantly higher in the surgical group (P = .03 and P = .01). Overall survival (P = .001) and progression-free survival (P = .001) were significantly higher in patients with pathological yp-Stage 0–1 compared to those with higher pathological stages. Conclusion: This study highlights the impact of pathological response rates following NACRT, with or without surgery, on treatment outcomes in esophageal cancer. Cite this article as: Çepni K, Uçgun TH, Şam Özdemir M, Aydın SN, Çepni B, Kızıltan HS. Impact of response rates on overall survival following chemoradiotherapy with or without surgery in esophageal cancer. Cerrahpaşa Med J 2026, 50, 0079, doi:10.5152/cjm.2026.25079.Keywords
This publication has 31 references indexed in Scilit:
- Pathologic complete response in patients with esophageal cancer receiving neoadjuvant chemotherapy or chemoradiation: A systematic review and meta‐analysisCancer Medicine, 2024
- LBA75 Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal cancer (SANO-trial): A phase-III stepped-wedge cluster randomised trialAnnals of Oncology, 2023
- Evaluation of Clinical and Safety Outcomes of Neoadjuvant Immunotherapy Combined With Chemotherapy for Patients With Resectable Esophageal CancerJAMA Network Open, 2022
- Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell CarcinomaJAMA Surgery, 2021
- The Role of Radiation Therapy in the Older PatientCurrent Oncology Reports, 2021
- Epidemiology of esophageal cancer: update in global trends, etiology and risk factorsClinical Journal of Gastroenterology, 2020
- Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trialThe Lancet, 2019
- Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta‐analysisInternational Journal of Cancer, 2018
- Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival—The University of Texas MD Anderson Cancer Center experienceCancer, 2017
- Association of Intervals Between Neoadjuvant Chemoradiation and Surgical Resection With Pathologic Complete Response and Survival in Patients With Esophageal CancerJAMA Surgery, 2016